WCVI 2010 - BIT¡¯s 1st World Congress of Virus and Infections-2010 (WCVI 2010)

Website http://www.bitlifesciences.com/wcvi2010 | Edit Freely

Category WCVI 2010

Deadline: December 31, 2009 | Date: July 31, 2010

Venue/Country: Busan, South Korea

Updated: 2010-06-04 19:32:22 (GMT+9)

Call For Papers - CFP

Virus and Infections-2010

(WCVI-2010)

Theme: Voice of Virologists

Time: July 31-August 3, 2010 Venue: Korea

Scientific Program

Symposium 1: World Congress of Virus and Infections

Track 1: Global Epidemics and Prevention

Track 1-1: Molecular Epidemiology of Emerging Virus Transmission and Distribution

Track 1-2: Molecular Epidemiology: Zoonoses, Recombination, and Co-infection

Track 1-3: Prevention and Prevention Interventions

Track 1-4: Human Resources, Infrastructure and Health Care Strengthening

Track 1-5: Operational Research in Prevention, Care, and Treatment

Track 1-6: Impact and Integration of Programmes

Track 2: General Virology and Basic Sciences

Track 2-1: Viruses from Structure to Biology

Track 2-2: Viral Genetics of Pathogen Transmission

Track 2-3: Viral Genomics and Proteomics

Track 2-4: Viral Replication Cycle

Track 2-5: Viral Tropism and Transmission

Track 2-6: Cellular Factors Affecting Viral Replication and Pathogenicity

Track 2-7: Physical Virology

Track 3: Medical and Clinical Virology

Track 3-1: Clinical Viral Diagnostics

Track 3-2: Emerging and Zoonotic infections

Track 3-3: Vector and Blood Borne Diseases

Track 3-4: Viral Infections of the CNS

Track 3-5: Viral Gastroenteritis

Track 4: Retrovirus-HIV/AIDS-Basic Sciences and Implications

Track 4-1: Entry

Track 4-2: Post-Entry

Track 4-3: Assembly / Release

Track 4-4: Integration

Track 4-5: Reverse Transcription / Recombination

Track 4-6: Pathogenesis / Host Factors

Track 4-7: Restriction Factors II

Track 4-8: Transcription/Processing/Export/Translation

Track 4-9: Packaging

Track 4-10: Accessory Proteins

Track 4-11: Immunology of HIV Infection

Track 4-12: Viral Diversity and Bioinformatics

Track 4-13: Mechanisms of HIV Transmission and Impact of Co-infection

Track 4-14: Diagnostics and Prognostics of HIV Infections

Track 4-15: Field Trials of Diagnosis and Monitoring Tools

Track 4-16: HIV-Associated Diseases

Track 4-17: Antiretroviral Therapies and Resistances

Track 4-18: Children and Adolescents-specific Issues

Track 4-19: Complications of Therapy and Adherence

Track 4-20: Biomedical Prevention -Prevention of Mother-to-Child Transmission

Track 4-21: Microbicide Research

Track 4-22: Preventive Vaccine Clinical Trials

Track 4-23: AIDS Vaccines (Basic and Animal Studies)

Track 5: Other Retrovirus Researches

Track 5-1: Alpharetrovirus

Track 5-2: Betaretrovirus

Track 5-3: Gammaretrovirus

Track 5-4: Deltaretrovirus- Bovine Leukaemia Virus

Track 5-5: Human T-lymphotropic Virus

Track 5-6: Epsilonretrovirus

Track 5-7: Simian Virus and Feline Immunodeficiency Viruses

Track 5-8: Spumavirus

Track 6: Respiratory and Emerging/Re-emerging Viruses

Track 6-1: Avian Flu H5N1

Track 6-2: Severe Acute Respiratory Syndrome (SARS) and Other Severe Viral Pneumonia

Track 6-3: Dengue Virus

Track 6-4: Herpes Viruses and Poxviruses

Track 6-5: RSV

Track 6-6: West Nile Virus

Track 6-7: Hantaviruses

Track 6-8: Filoviruses- Ebola virus

Track 6-9: Japanese Encephalitis

Track 6-10: Influenza A (H1N1) Virus

Track 7: Neuro-Viorology

Track 7-1: Mechanisms of Viral Neuropathogenesis

Track 7-2: NeuroAIDS Complications

Track 7-3: Aging and Metabolic Syndromes of Neurologic Disorders by Viruses

Track 7-4: Molecular diagnosis of CNS Viral infections

Track 8: Pediatric Viral Infectious Diseases

Track 8-1: Viral Skin Infections, Prevention and Treatment

Track 8-2: Respiratory Syncytial Virus Infection ?Prevention

Track 8-3: Rotavirus Vaccine and Children Diarrheal Prevention and Treatment

Track 8-4: Mouth and Hand Virus Infection and Management

Track 8-5: Other Virus Infections in Children and Management

Track 9: Human Tumor Virology

Track 9-1: Tumor Virology and Immunology

Track 9-2: Polyomavirus Infections Associated Cancer

Track 9-3: HPV Infection Associated Cervical Cancer

Track 9-4: Human Herpes Virus 8 in Kaposi-Sarcoma

Track 9-5: Epstein - Barr Virus and Cancers

Track 9-6: Human T Cell Leukemia Virus Type 1

Track 9-7: Simian Virus 40 in Cancers

Track 9-8: HIV Associated Squamous Cell Cancer

Track 9-9: Avian Leucosis Virus and Cancers

Track 10: Viral Immunology, Infection and Immunity

Track 10-1: Pathogenesis, Humoral Responses and Immune Receptor Diversification

Track 10-2: Innate Immunity & Specific Immunity

Track 10-3: Mucosal Immunity

Track 10-4: Neutralization and Evolution of Viral Antigens

Track 10-5: Types of Virus-specific Antibodies

Track 10-6: Specificity of Test Methods

Track 10-7: Cell-Mediated Immunity and Antibody-dependent Cell-mediated Cytotoxicity

Track 10-8: Natural Killer (NK) cells

Track 10-9: RNAi in Immunity Research

Track 11: Agriculture and Plant Virology

Track 11-1: Wheat and Rice Virus

Track 11-2: Tobacco Virus and the Economic Implications

Track 11-3: Potato and Bean Virus

Track 11-4: Other Vegetable Virus

Track 11-5: The Plant Virus Biodiversity, Ecology and Molecular Virology

Track 11-6: Viral Counter-defense Proteins

Track 11-7: Tospoviruses

Track 11-8: RNAi in Plant Virus

Track 11-9: Viral Pathogen and Plant Disease Control

Track 11-10: Plant Virus' Contributions to Green Biotech Products

Track 12: Veterinary Virology

Track 12-1: Viral Molecular Diagnosis and Diseases Control

Track 12-2: Animal Vaccines and Viral Immunology

Track 12-3: Host-virus interactions and pathogenesis and Prion Disease

Track 12-4: Emerging Viruses and Zoonoses Epidemiology

Track 12-5: Veterinary Viral Functional Genomics and Proteomics

Symposium 2: Inaugurate Symposium of Hepatitis Virus

Track 1: Hepatisis C Virus

Track 1-1: Hepatitis C: Basic Virology & Immunology

Track 1-2: Hepatitis C Clinical Course and Therapy

Track 1-3: HCV Virology

Track 1-4: HCV Quasispecies & Kinetics

Track 1-5: Natural History of Hepatitis C

Track 1-6: New Agents for Hepatitis C Clinical

Track 1-7: HCV Immunology & Vaccines

Track 1-8: HCV Epidemiology

Track 1-9: Immunology of HCV Infection

Track 1-10: HCV Cell Biology & Antiviral Effects

Track 1-11: New Therapies for Hepatitis C: Preclinical

Track 1-12: Therapy of Hepatitis C: Current Issues

Track 1-13: HIV Co-infection (HBV & HCV)

Track 2: Hepatitis B and D Virus

Track 2-1: Hepatitis B and D: Basic Virology & Immunology

Track 2-2: Hepatitis B Therapy (I)

Track 2-3: HBV Virology

Track 2-4: Latent & Occult HBV Infection

Track 2-5: HBV Therapy (I)

Track 2-6: HBV Epidemiology

Track 2-7: Issues in Control of HBV

Track 2-8: HBV Virology

Track 2-9: HBV Immunology

Track 2-10: HBV Vaccine & Prevention

Track 2-11: Other Hepatitis

Track 2-12: Antiviral Resistance & HBV

Track 2-13: Experimental Approaches to Therapy of HBV

Track 2-14: Natural History of HBV

Track 3: Hepatitis A and E Virus

Track 3-1: Hepatitis A Virus and Hepatitis E Virus

Track 3-2: Global Control of Viral Hepatitis

Track 3-3: HAV Virology

Track 3-4: HEV Virology

Track 3-5: HEV Pathogenesis

Track 3-6: HEV Epidemiology

Track 3-6: HAV Epidemiology

Track 4: Virus and Liver Cancer

Track 4-1: Hepatocellular Carcinoma (HCC)

Track 4-2: Epidemiology of HCC

Track 4-3: Biomarkers for HCC

Track 4-4: Therapy of HCC

Symposium 3: World Summit of Antivirals

Track 1: Targeting Drug Discovery and Development-Small Molecules

Track 1-1: Targeting Entry of HIV

Track 1-2: Transcriptase Inhibitors and DNA Polymerase Inhibitors

Track 1-3: Protease Inhibitors

Track 1-4: Targeting Assembly / Release

Track 1-5: Targeting Integrase by Inhibitors

Track 1-6: Targeting Reverse Transcription / Recombination

Track 1-7: Targeting Cytokines and Protein Kinases

Track 1-8: Targeting Transcription/Processing/Export/Translation

Track 1-9: Anti Avian Flu Drug Discovery

Track 1-10: Hepatitis Virus Small Molecule Drug Development

Track 1-11: New HIV Chemotherapeutics Development

Track 1-12: Nanotechnology and Delivery Technologies for Antivirals

Track 2: Antiviral Vaccine Development

Track 2-1: Cytomegalovirus Vaccines

Track 2-2: Dengue Vaccines

Track 2-3: Hepatitis B-Emergent Bio-Solutions

Track 2-4: HCV Vaccines

Track 2-5: Herpes Simplex Virus Vaccines

Track 2-6: Human Papilloma virus (HPV)

Track 2-7: Influenza Vaccines

Track 2-8: Respiratory Syncytial Virus Vaccines

Track 2-9: West Nile Virus Vaccines

Track 2-10: Other Emerging Infectious Disease Vaccines

Track 3: Imunotherapy and Therapeutic Antibodies

Track 3-1: Novel Immune-based Therapies

Track 3-2: Recombinant Simian Glycosylated Interleukin-7 Prevents

Track 3-3: Toll-like Receptor-7 Signaling and Interferon

Track 3-4: Therapeutic Expression of Fusion Inhibitory C Peptides

Track 3-5: Immune Therapies Involving Interleukin-2

Track 3-6: Immune Stimulatory Capacity of Dendritic Cells

Track 3-7: Interleukin-2 Adjuvant Therapy

Track 3-8: Monoclonal Antibodies against HCV

Track 3-9: Monoclonal Antibodies against Herpes Virus

Track 3-10: Monoclonal Antibodies against Human Immunodeficiency Virus (HIV)

Track 4: Gene Therapy for Viral Infections

Track 4-1: RNAi Applications in HIV/AIDS

Track 4-2: Viral Vectors for Gene Therapy

Track 4-3: Targeting CXCR4 with siRNA

Track 4-4: Antisense Oligodeoxynucleotide

Track 4-5: DNA Vaccines on Viral Infections

Track 4-6: Genetic Vaccines for Other Viral Infection